InsiderTrades.com logo

INKT Insider Trading

Insider Ownership Percentage: 22.48%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $27,481.00

MiNK Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at MiNK Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MiNK Therapeutics Share Price & Price History

Current Price: $14.21
Price Change: ▲ Price Increase of +0.08 (0.57%)
As of 04/17/2026 05:00 PM ET

This chart shows the closing price history over time for INKT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

MiNK Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/10/2026Barbara RyanDirectorSell1,300$15.40$20,020.0020,406View SEC Filing Icon  
3/9/2026Barbara RyanDirectorSell200$10.17$2,034.0021,706View SEC Filing Icon  
3/2/2026Barbara RyanDirectorSell100$10.83$1,083.0021,906View SEC Filing Icon  
2/27/2026Barbara RyanDirectorSell400$10.86$4,344.0022,006View SEC Filing Icon  
10/16/2023Agenus IncMajor ShareholderBuy42$11.00$462.002,177,286View SEC Filing Icon  
10/12/2023Agenus IncMajor ShareholderBuy317$11.00$3,487.002,175,306View SEC Filing Icon  
10/4/2023Agenus IncMajor ShareholderBuy1,500$10.90$16,350.002,174,988View SEC Filing Icon  
8/28/2023Agenus IncMajor ShareholderBuy1,280$14.50$18,560.002,170,520View SEC Filing Icon  
8/24/2023Agenus IncMajor ShareholderBuy17,024$15.40$262,169.602,169,240View SEC Filing Icon  
5/10/2023Agenus IncMajor ShareholderBuy2,206$15.10$33,310.602,161,711View SEC Filing Icon  
5/5/2023Agenus IncMajor ShareholderBuy10,020$9.50$95,190.002,159,504View SEC Filing Icon  
5/5/2023Garo H ArmenDirectorSell10,000$9.50$95,000.00186,640View SEC Filing Icon  
5/3/2023Agenus IncMajor ShareholderBuy12,868$10.80$138,974.402,147,337View SEC Filing Icon  
5/2/2023Garo H ArmenDirectorBuy10,000$9.50$95,000.00197,801View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for MiNK Therapeutics (NASDAQ:INKT)

2.87% of MiNK Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INKT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

MiNK Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/12/2026DRW Securities LLC25,677$0.29M0.0%N/A0.547%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC10,400$0.12M0.0%-28.8%0.222%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC14,247$0.16M0.0%+11.3%0.304%Search for SEC Filing on Google Icon
5/7/2025Longbow Finance SA16,667$0.14M0.0%-90.0%0.420%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC101,707$71K0.0%-4.7%2.566%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC96,113$67K0.0%-1.9%2.427%Search for SEC Filing on Google Icon
2/7/2025HighTower Advisors LLC50,676$35K0.0%-2.0%1.280%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC127,841$0.12M0.0%+21.5%0.368%Search for SEC Filing on Google Icon
11/14/2023Oracle Investment Management Inc.36,898$41K0.0%-26.9%0.107%Search for SEC Filing on Google Icon
8/14/2023Oracle Investment Management Inc.50,461$0.11M0.1%N/A0.146%Search for SEC Filing on Google Icon
8/14/2023Deep Track Capital LP324,867$0.68M0.0%N/A0.941%Search for SEC Filing on Google Icon
8/11/2023Artal Group S.A.228,216$0.48M0.0%-21.2%0.663%Search for SEC Filing on Google Icon
7/27/2023Virtu Financial LLC14,232$30K0.0%N/A0.041%Search for SEC Filing on Google Icon
2/10/2023StoneX Group Inc.17,821$47K0.0%N/A0.053%Search for SEC Filing on Google Icon
11/4/2022First Republic Investment Management Inc.81,500$0.17M0.0%N/A0.243%Search for SEC Filing on Google Icon
2/15/2022Sofinnova Investments Inc.345,499$1.54M0.1%N/A1.031%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
MiNK Therapeutics logo
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More on MiNK Therapeutics

Today's Range

Now: $14.21
Low: $13.01
High: $14.88

50 Day Range

MA: $10.94
Low: $8.56
High: $14.21

52 Week Range

Now: $14.21
Low: $6.34
High: $76.00

Volume

150,829 shs

Average Volume

63,251 shs

Market Capitalization

$70.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Who are the company insiders with the largest holdings of MiNK Therapeutics?

MiNK Therapeutics' top insider shareholders include:
  1. Agenus Inc (Major Shareholder)
  2. Garo H Armen (Director)
  3. Ulf Wiinberg (Director)
  4. Barbara Ryan (Director)
Learn More about top insider investors at MiNK Therapeutics.